title: Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran.
abstract: METHODS
  Masih Daneshvari Hospital, Tehran, Iran, 2000-2002.
  
  
  OBJECTIVE
  To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran.
  
  
  METHODS
  All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated.
  
  
  RESULTS
  MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen.
  
  
  CONCLUSIONS
  A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.
authors.affiliation: Department of Tuberculosis and Respiratory Infections, Iranian National Research Institute of Tuberculosis and Lung Diseases, Tehran 19556, Iran. mmirsaeidi@nritld.ac.ir
authors.forename: Seyed Mehdi
authors.initials: SM
authors.lastname: Mirsaeidi
authors.forename: Payam
authors.initials: P
authors.lastname: Tabarsi
authors.forename: Kaveh
authors.initials: K
authors.lastname: Khoshnood
authors.forename: Majid Valiollah
authors.initials: MV
authors.lastname: Pooramiri
authors.forename: Ali
authors.initials: A
authors.lastname: Rowhani-Rahbar
authors.forename: Seyed Davood
authors.initials: SD
authors.lastname: Mansoori
authors.forename: Heydar
authors.initials: H
authors.lastname: Masjedi
authors.forename: Soheyla
authors.initials: S
authors.lastname: Zahirifard
authors.forename: Foroozan
authors.initials: F
authors.lastname: Mohammadi
authors.forename: Parisa
authors.initials: P
authors.lastname: Farnia
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Masjedi
authors.forename: Ali Akbar
authors.initials: AA
authors.lastname: Velayati
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003523:Cycloserine / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007492:Iran; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents; D000583:Amikacin; D003523:Cycloserine; D015242:Ofloxacin; D007538:Isoniazid